EI
MNPR icon

EAM Investors’s Monopar Therapeutics MNPR Stock Holding History

EAM Investors’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$341K Sell
6,225
-5,148
-45% -$311K 0.04% 272
2025
Q4 		$743K Sell
11,373
-3,256
-22% -$266K 0.08% 235
2025
Q3 		$1.19M Buy
+14,629
New +$654K 0.14% 181

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

EAM Investors's MNPR Position: Q1 2026 in Review

EAM Investors reduced its Monopar Therapeutics (MNPR) stake by 45% in Q1 2026, selling an estimated $311K and leaving 6,225 shares worth $341K. The position accounts for 0.04% of the portfolio, ranked #272.

EAM Investors first reported a position in MNPR in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.19M in Q3 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • EAM Investors held 6,225 shares of Monopar Therapeutics worth $341K as of Q1 2026.
  • EAM Investors sold 5,148 Monopar Therapeutics shares in Q1 2026, an estimated $311K.
  • Monopar Therapeutics made up 0.04% of EAM Investors's portfolio in Q1 2026, its #272 holding.
  • EAM Investors first reported a position in Monopar Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • EAM Investors's Monopar Therapeutics position peaked at $1.19M in Q3 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on EAM Investors's 13F filing for Q1 2026, filed 13 May 2026.